11 Results

People

  1. Drullinsky
    Drullinsky
  2. Zelenetz
    Zelenetz
  3. Gerecitano
    Gerecitano
  4. Hamlin
    Hamlin
  5. Kumar
    Kumar
  6. Matasar
    Matasar
  7. Moskowitz
    Moskowitz
  8. Straus
    Straus
  9. Younes
    Younes
  10. D'Andrea-Carlino
    D'Andrea-Carlino

Groups

  1. Breast Medicine Service (11)
  2. Department of Medicine (11)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (8)
  5. Hematologic Malignancies, Division of (8)
  6. Survivorship Research (7)
  7. Epidemiology and Biostatistics (5)
  8. Lymphoma (5)
  9. Biostatistics Service (4)
  10. Radiology, Department of (4)
  1. "clinical article"
  2. "Pamela Drullinsky"
Formats
  1. Journal Article (10)
  2. Research Letter (1)
Groups
  1. Breast Medicine Service (11)
  2. Department of Medicine (11)
  3. Solid Tumor Oncology Division (11)
  4. Center for Hematologic Malignancies (8)
  5. Hematologic Malignancies, Division of (8)
  6. Survivorship Research (7)

More Groups

People
  1. Pamela Drullinsky (11)
  2. Andrew Zelenetz (5)
  3. Anita Kumar (4)
  4. John Gerecitano (4)
  5. Paul Hamlin (4)
  6. Anas Younes (3)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2020 (1)
  4. 2018 (1)
  5. 2015 (1)
  6. 2012 (2)

More Years

Publications
  1. Leukemia and Lymphoma (3)
  2. Breast Cancer Research and Treatment (2)
  3. Leukemia (2)
  4. Blood (1)
  5. British Journal of Haematology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Taylor & Francis Group (3)
  2. Nature Publishing Group (2)
  3. Springer (2)
  4. American Association for Cancer Research (1)
  5. American Society of Hematology (1)
  6. Elsevier Inc. (1)

More Publishers

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Journal Article

    Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
    Journal Article

    Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Lia Palomba, M.; Drullinsky, P. R.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Elstrom, R.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
    Journal Article

    Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
    Leukemia and Lymphoma (2012)

    Fulltext@MSK | Save
  • Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Journal Article

    Gajria, D.; Gonzalez, J.; Feigin, K.; Patil, S.; Chen, C.; Theodoulou, M.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia
    Journal Article

    Weiss, M. A.; Drullinsky, P.; Maslak, P.; Scheinberg, D.; Golde, D. W.
    Leukemia (1998)

    Fulltext@MSK | Save